Retrospective cohort study on combination therapy with the histamine H2-receptor antagonist lafutidine for antihistamine-resistant chronic urticaria. (December 2013)

• Record Type: Journal Article
• Authors: Ogawa, Yumi; Ichinokawa, Yuko; Hiruma, Midori; Machida, Yuko; Funakushi, Naoko; Sadamasa, Hiroko; Hiruma, Masataro
• Is Part Of: Journal of dermatological treatment. Volume 24:Number 6(2013:Dec.)
• Page Start: 463
• Page End: 465
• Publication Date: 2013-12
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2013.800183
• Languages: English
• ISSNs: 0954-6634

Abstract

<abstract> <title /> <p>We conducted a retrospective cohort study evaluating the efficacy and usefulness of the addition of lafutidine, a novel histamine H2-receptor antagonist, in treatment of patients with idiopathic chronic urticaria whose disease was not well controlled with histamine H1-receptor antagonists. Based on the assessment of global improvement, moderate or better improvement was achieved in 39 of 46 patients (85%) after 1–3 weeks of additional administration of lafutidine and 35 patients (76%) after 3 months. No incidence of drug-related adverse reactions was reported in any patient. Lafutidine was rated as useful or better in 34 patients (74%) after 3 months of treatment. The usefulness of the drug was not affected by differences in background factors, such as disease duration, previous treatment duration and the number of concomitant H1-receptor antagonists. Lafutidine appears to be a promising addition to histamine H1-receptor antagonist therapy for the treatment of chronic urticaria resistant to treatment with H1-receptor antagonists alone.</p> </abstract>